header logo image

Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy – Endpoints News

September 3rd, 2020 5:50 pm

Fouad Namouni, a storied research exec who went from project leader on Opdivo and Yervoy to the top of the oncology research group at Bristol Myers Squibb, is joining the migration to biotech, picking up a new hat as president of R&D at Blueprint Medicines.

Once again, hes headed into a toe-to-toe showdown with a rival pharma organization.

Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprints RET rival to Eli Lillys Retevmo, which got out in front with a May approval. Ironically, Lillys deal to buy into RET with its acquisition of Loxo also brought Josh Bilenker and his crew to the pharma giant, marking a rare career trajectory from a biotech into pharma, which has been bleeding talent for years now.

Unlock this story instantly and join 89,400+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continued here:
Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it's a doozy - Endpoints News

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick